Company Overview
CapsoVision, Inc. operates as a medical technology company dedicated to the manufacture and marketing of endoscopic video imaging devices specifically designed for the internal imaging of the gastrointestinal system. The firm focuses on offering products such as the CapsoCam Plus, a capsule endoscopy system utilized for the visualization of small bowel mucosa in both adults and children aged 2 years and older. This entity functions within the Healthcare sector, specifically the Medical Devices industry, positioning itself to serve the specialized needs of gastroenterology practices requiring advanced imaging capabilities. With a market capitalization of $411.10M, annual revenue of $13.09M, and an employee count of 90, the company represents a mid-sized enterprise with significant operational focus relative to its financial scale. These valuation and revenue figures indicate a company that maintains a substantial market cap in relation to its reported revenue, suggesting a high valuation multiple often associated with growth-stage biotech or medical device firms where future potential is priced into the current equity rather than current cash flows.
Financial Health
The company reported revenue of $13.09M over the trailing twelve months, yet generated net income of $-22,560,000, while EBITDA stood at $-22,474,000. The substantial gap between the $13.09M revenue and the negative net income reveals a highly leveraged cost structure where expenses significantly exceed top-line generation, resulting in a loss that is nearly double the revenue figure. Free cash flow is listed as N/A, which implies that the company is currently burning cash or has not yet reached a stage of positive cash generation, indicating limited financial flexibility for debt repayment or heavy capital expenditure without external financing. The gross margin stands at 53.1%, suggesting a favorable pricing power or high-margin manufacturing process for the core device, whereas the operating margin of -226.7% and profit margin of -172.4% highlight severe operational inefficiencies or high fixed costs relative to current sales volume. Total cash holdings amount to $17.79M, which exceeds the total debt of $978,000, yet the debt-to-equity ratio of 4.78 indicates a highly leveraged balance sheet structure relative to shareholder equity. The current ratio of 5.19 demonstrates strong short-term liquidity, suggesting the company holds ample current assets to cover its current liabilities despite the negative earnings position. Return on Equity and Return on Assets are both N/A due to the lack of net income, which reveals that management has not yet been effective in generating returns on the capital invested by shareholders or utilized in assets.
Valuation Assessment
The trailing P/E ratio and forward P/E are both N/A, reflecting the company's unprofitable status and implying that traditional earnings-based valuation models are not applicable at this time. The price-to-book ratio is 18.92, indicating a significant market premium over the company's book value, which often signals high investor expectations for future growth or technological moats that are not reflected on the balance sheet. The price-to-sales ratio is 31.41, and the EV/EBITDA is -16.49, suggesting that the market is valuing the firm based on revenue generation and potential rather than current profitability or enterprise value relative to earnings. The stock has traded between a 52-week low of $3.43 and a 52-week high of $15.37; without a specific current price provided in the facts, the valuation range indicates a volatility of over 300% from the recent lows to the highs. The beta value is N/A, which means there is insufficient data to determine the price volatility relative to the broader market, preventing a direct comparison of risk levels against the S&P 500.
Growth & Income
Revenue growth year-over-year is 19.3%, while earnings growth is N/A due to the company's continued losses, implying that top-line expansion is occurring without a corresponding improvement in profitability. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash flow is theoretically reinvested into growth initiatives, R&D, or operational scaling rather than distributed to shareholders. The absence of a dividend payout ratio being sustainable is moot since no dividends are paid, but the reinvestment of earnings into growth is the primary driver for the current revenue expansion trajectory. The overall growth and income profile presents a scenario of aggressive revenue expansion coupled with significant cash burn and no current income generation for investors, typical of early-stage medical device companies attempting to capture market share.